nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—ALB—Vismodegib—skin cancer	0.297	0.466	CbGbCtD
Ceftriaxone—ALB—Vemurafenib—skin cancer	0.235	0.368	CbGbCtD
Ceftriaxone—ALB—Fluorouracil—skin cancer	0.105	0.166	CbGbCtD
Ceftriaxone—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.00252	0.00726	CcSEcCtD
Ceftriaxone—GLUL—hair follicle—skin cancer	0.0025	0.157	CbGeAlD
Ceftriaxone—Eosinophilia—Vemurafenib—skin cancer	0.00239	0.0069	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.00214	0.00616	CcSEcCtD
Ceftriaxone—Tenderness—Fluorouracil—skin cancer	0.00208	0.006	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Dactinomycin—skin cancer	0.00205	0.00589	CcSEcCtD
Ceftriaxone—Sweating increased—Imiquimod—skin cancer	0.00201	0.00579	CcSEcCtD
Ceftriaxone—Vaginal inflammation—Temozolomide—skin cancer	0.00197	0.00568	CcSEcCtD
Ceftriaxone—Phlebitis—Bleomycin—skin cancer	0.00197	0.00567	CcSEcCtD
Ceftriaxone—Dyspepsia—Vismodegib—skin cancer	0.00196	0.00565	CcSEcCtD
Ceftriaxone—Leukocytosis—Fluorouracil—skin cancer	0.00193	0.00557	CcSEcCtD
Ceftriaxone—Pain—Vismodegib—skin cancer	0.0019	0.00549	CcSEcCtD
Ceftriaxone—Candida infection—Temozolomide—skin cancer	0.00188	0.00542	CcSEcCtD
Ceftriaxone—Vaginal infection—Temozolomide—skin cancer	0.00186	0.00536	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Temozolomide—skin cancer	0.00185	0.00533	CcSEcCtD
Ceftriaxone—Phlebitis—Dactinomycin—skin cancer	0.00184	0.00529	CcSEcCtD
Ceftriaxone—Erythema multiforme—Vemurafenib—skin cancer	0.00183	0.00527	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.00182	0.00525	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Vismodegib—skin cancer	0.00182	0.00525	CcSEcCtD
Ceftriaxone—Dermatitis atopic—Docetaxel—skin cancer	0.00177	0.0051	CcSEcCtD
Ceftriaxone—Abdominal pain—Vismodegib—skin cancer	0.00176	0.00507	CcSEcCtD
Ceftriaxone—Chills—Vemurafenib—skin cancer	0.00174	0.00501	CcSEcCtD
Ceftriaxone—GLUL—neck—skin cancer	0.00168	0.105	CbGeAlD
Ceftriaxone—Haemoglobin—Imiquimod—skin cancer	0.00166	0.00478	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Temozolomide—skin cancer	0.00165	0.00476	CcSEcCtD
Ceftriaxone—Haemorrhage—Imiquimod—skin cancer	0.00165	0.00476	CcSEcCtD
Ceftriaxone—Dysgeusia—Vemurafenib—skin cancer	0.00165	0.00476	CcSEcCtD
Ceftriaxone—Pruritus—Vismodegib—skin cancer	0.00158	0.00454	CcSEcCtD
Ceftriaxone—Erythema multiforme—Imiquimod—skin cancer	0.00156	0.0045	CcSEcCtD
Ceftriaxone—Flushing—Imiquimod—skin cancer	0.00153	0.00442	CcSEcCtD
Ceftriaxone—Diarrhoea—Vismodegib—skin cancer	0.00152	0.00439	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Fluorouracil—skin cancer	0.00152	0.00439	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Temozolomide—skin cancer	0.00152	0.00437	CcSEcCtD
Ceftriaxone—Chills—Imiquimod—skin cancer	0.00148	0.00427	CcSEcCtD
Ceftriaxone—Bronchospasm—Bleomycin—skin cancer	0.00144	0.00415	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00142	0.0041	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.00142	0.0041	CcSEcCtD
Ceftriaxone—Oliguria—Docetaxel—skin cancer	0.00142	0.0041	CcSEcCtD
Ceftriaxone—Vomiting—Vismodegib—skin cancer	0.00142	0.00408	CcSEcCtD
Ceftriaxone—Drug interaction—Docetaxel—skin cancer	0.00141	0.00407	CcSEcCtD
Ceftriaxone—Rash—Vismodegib—skin cancer	0.0014	0.00405	CcSEcCtD
Ceftriaxone—Dermatitis—Vismodegib—skin cancer	0.0014	0.00404	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Vemurafenib—skin cancer	0.00138	0.00396	CcSEcCtD
Ceftriaxone—Infection—Vemurafenib—skin cancer	0.00137	0.00394	CcSEcCtD
Ceftriaxone—Ataxia—Temozolomide—skin cancer	0.00134	0.00388	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Imiquimod—skin cancer	0.00133	0.00384	CcSEcCtD
Ceftriaxone—Nausea—Vismodegib—skin cancer	0.00132	0.00381	CcSEcCtD
Ceftriaxone—Agitation—Imiquimod—skin cancer	0.00132	0.00381	CcSEcCtD
Ceftriaxone—Malaise—Imiquimod—skin cancer	0.0013	0.00373	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.00129	0.00371	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00129	0.00371	CcSEcCtD
Ceftriaxone—Neutropenia—Dactinomycin—skin cancer	0.00128	0.00368	CcSEcCtD
Ceftriaxone—Stomatitis—Bleomycin—skin cancer	0.00127	0.00367	CcSEcCtD
Ceftriaxone—Palpitations—Imiquimod—skin cancer	0.00127	0.00366	CcSEcCtD
Ceftriaxone—Colitis—Docetaxel—skin cancer	0.00126	0.00363	CcSEcCtD
Ceftriaxone—Candida infection—Docetaxel—skin cancer	0.00125	0.0036	CcSEcCtD
Ceftriaxone—Haematuria—Bleomycin—skin cancer	0.00125	0.00359	CcSEcCtD
Ceftriaxone—Convulsion—Imiquimod—skin cancer	0.00125	0.00359	CcSEcCtD
Ceftriaxone—Ataxia—Fluorouracil—skin cancer	0.00124	0.00357	CcSEcCtD
Ceftriaxone—Discomfort—Imiquimod—skin cancer	0.00121	0.00348	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.00121	0.00348	CcSEcCtD
Ceftriaxone—Sweating increased—Temozolomide—skin cancer	0.0012	0.00347	CcSEcCtD
Ceftriaxone—GLUL—connective tissue—skin cancer	0.0012	0.0753	CbGeAlD
Ceftriaxone—Stomatitis—Dactinomycin—skin cancer	0.00119	0.00342	CcSEcCtD
Ceftriaxone—Haemoglobin—Bleomycin—skin cancer	0.00118	0.0034	CcSEcCtD
Ceftriaxone—Oedema—Imiquimod—skin cancer	0.00117	0.00338	CcSEcCtD
Ceftriaxone—Haemorrhage—Bleomycin—skin cancer	0.00117	0.00338	CcSEcCtD
Ceftriaxone—Infection—Imiquimod—skin cancer	0.00117	0.00336	CcSEcCtD
Ceftriaxone—Neutropenia—Temozolomide—skin cancer	0.00116	0.00333	CcSEcCtD
Ceftriaxone—GLUL—epithelium—skin cancer	0.00114	0.0715	CbGeAlD
Ceftriaxone—Agranulocytosis—Dactinomycin—skin cancer	0.00114	0.00328	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Imiquimod—skin cancer	0.00113	0.00327	CcSEcCtD
Ceftriaxone—Eosinophilia—Fluorouracil—skin cancer	0.00113	0.00325	CcSEcCtD
Ceftriaxone—Phlebitis—Docetaxel—skin cancer	0.0011	0.00318	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Docetaxel—skin cancer	0.0011	0.00317	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.00109	0.00315	CcSEcCtD
Ceftriaxone—Flushing—Bleomycin—skin cancer	0.00109	0.00314	CcSEcCtD
Ceftriaxone—Body temperature increased—Vemurafenib—skin cancer	0.00109	0.00313	CcSEcCtD
Ceftriaxone—GLUL—skin of body—skin cancer	0.00109	0.068	CbGeAlD
Ceftriaxone—Stomatitis—Temozolomide—skin cancer	0.00107	0.0031	CcSEcCtD
Ceftriaxone—Paraesthesia—Imiquimod—skin cancer	0.00105	0.00304	CcSEcCtD
Ceftriaxone—Chills—Bleomycin—skin cancer	0.00105	0.00303	CcSEcCtD
Ceftriaxone—Erythema multiforme—Dactinomycin—skin cancer	0.00103	0.00298	CcSEcCtD
Ceftriaxone—Dyspepsia—Imiquimod—skin cancer	0.00103	0.00298	CcSEcCtD
Ceftriaxone—Flushing—Dactinomycin—skin cancer	0.00102	0.00293	CcSEcCtD
Ceftriaxone—Hypersensitivity—Vemurafenib—skin cancer	0.00101	0.00292	CcSEcCtD
Ceftriaxone—Pain—Imiquimod—skin cancer	0.001	0.00289	CcSEcCtD
Ceftriaxone—Renal impairment—Docetaxel—skin cancer	0.000999	0.00288	CcSEcCtD
Ceftriaxone—Haemoglobin—Temozolomide—skin cancer	0.000994	0.00287	CcSEcCtD
Ceftriaxone—GLUL—mammalian vulva—skin cancer	0.000991	0.062	CbGeAlD
Ceftriaxone—Stomatitis—Fluorouracil—skin cancer	0.00099	0.00285	CcSEcCtD
Ceftriaxone—Haemorrhage—Temozolomide—skin cancer	0.000989	0.00285	CcSEcCtD
Ceftriaxone—Chills—Dactinomycin—skin cancer	0.000982	0.00283	CcSEcCtD
Ceftriaxone—Pruritus—Vemurafenib—skin cancer	0.000973	0.0028	CcSEcCtD
Ceftriaxone—Feeling abnormal—Imiquimod—skin cancer	0.000967	0.00279	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Imiquimod—skin cancer	0.000959	0.00276	CcSEcCtD
Ceftriaxone—Epistaxis—Fluorouracil—skin cancer	0.000958	0.00276	CcSEcCtD
Ceftriaxone—Agranulocytosis—Fluorouracil—skin cancer	0.000948	0.00273	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Bleomycin—skin cancer	0.000947	0.00273	CcSEcCtD
Ceftriaxone—SLC15A1—epithelium—skin cancer	0.000944	0.0591	CbGeAlD
Ceftriaxone—Anaemia—Bleomycin—skin cancer	0.000944	0.00272	CcSEcCtD
Ceftriaxone—Diarrhoea—Vemurafenib—skin cancer	0.000941	0.00271	CcSEcCtD
Ceftriaxone—Erythema multiforme—Temozolomide—skin cancer	0.000936	0.0027	CcSEcCtD
Ceftriaxone—Urticaria—Imiquimod—skin cancer	0.000932	0.00269	CcSEcCtD
Ceftriaxone—Body temperature increased—Imiquimod—skin cancer	0.000927	0.00267	CcSEcCtD
Ceftriaxone—Abdominal pain—Imiquimod—skin cancer	0.000927	0.00267	CcSEcCtD
Ceftriaxone—Malaise—Bleomycin—skin cancer	0.000921	0.00265	CcSEcCtD
Ceftriaxone—Flushing—Temozolomide—skin cancer	0.000918	0.00265	CcSEcCtD
Ceftriaxone—Haemoglobin—Fluorouracil—skin cancer	0.000916	0.00264	CcSEcCtD
Ceftriaxone—Leukopenia—Bleomycin—skin cancer	0.000914	0.00263	CcSEcCtD
Ceftriaxone—Haemorrhage—Fluorouracil—skin cancer	0.000912	0.00263	CcSEcCtD
Ceftriaxone—Dizziness—Vemurafenib—skin cancer	0.00091	0.00262	CcSEcCtD
Ceftriaxone—Ataxia—Docetaxel—skin cancer	0.000894	0.00258	CcSEcCtD
Ceftriaxone—SLC22A11—female reproductive system—skin cancer	0.000894	0.056	CbGeAlD
Ceftriaxone—Chills—Temozolomide—skin cancer	0.000888	0.00256	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Dactinomycin—skin cancer	0.000884	0.00255	CcSEcCtD
Ceftriaxone—Anaemia—Dactinomycin—skin cancer	0.00088	0.00254	CcSEcCtD
Ceftriaxone—GLUL—lymphoid tissue—skin cancer	0.00088	0.055	CbGeAlD
Ceftriaxone—Vomiting—Vemurafenib—skin cancer	0.000875	0.00252	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Docetaxel—skin cancer	0.000869	0.0025	CcSEcCtD
Ceftriaxone—Rash—Vemurafenib—skin cancer	0.000867	0.0025	CcSEcCtD
Ceftriaxone—Dermatitis—Vemurafenib—skin cancer	0.000866	0.0025	CcSEcCtD
Ceftriaxone—Hypersensitivity—Imiquimod—skin cancer	0.000864	0.00249	CcSEcCtD
Ceftriaxone—Headache—Vemurafenib—skin cancer	0.000862	0.00248	CcSEcCtD
Ceftriaxone—Discomfort—Bleomycin—skin cancer	0.000859	0.00247	CcSEcCtD
Ceftriaxone—Malaise—Dactinomycin—skin cancer	0.000859	0.00247	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.000857	0.00247	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000857	0.00247	CcSEcCtD
Ceftriaxone—Leukopenia—Dactinomycin—skin cancer	0.000852	0.00246	CcSEcCtD
Ceftriaxone—GLUL—female reproductive system—skin cancer	0.000848	0.0531	CbGeAlD
Ceftriaxone—Dysgeusia—Temozolomide—skin cancer	0.000843	0.00243	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Bleomycin—skin cancer	0.000833	0.0024	CcSEcCtD
Ceftriaxone—Oedema—Bleomycin—skin cancer	0.000833	0.0024	CcSEcCtD
Ceftriaxone—Pruritus—Imiquimod—skin cancer	0.00083	0.00239	CcSEcCtD
Ceftriaxone—Infection—Bleomycin—skin cancer	0.000828	0.00239	CcSEcCtD
Ceftriaxone—SLC15A1—mammalian vulva—skin cancer	0.000819	0.0512	CbGeAlD
Ceftriaxone—Nausea—Vemurafenib—skin cancer	0.000817	0.00235	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Bleomycin—skin cancer	0.000816	0.00235	CcSEcCtD
Ceftriaxone—Bronchospasm—Docetaxel—skin cancer	0.000809	0.00233	CcSEcCtD
Ceftriaxone—Diarrhoea—Imiquimod—skin cancer	0.000803	0.00231	CcSEcCtD
Ceftriaxone—Discomfort—Dactinomycin—skin cancer	0.000801	0.00231	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Temozolomide—skin cancer	0.000799	0.0023	CcSEcCtD
Ceftriaxone—Anaemia—Temozolomide—skin cancer	0.000796	0.00229	CcSEcCtD
Ceftriaxone—Agitation—Temozolomide—skin cancer	0.000792	0.00228	CcSEcCtD
Ceftriaxone—Oedema—Dactinomycin—skin cancer	0.000777	0.00224	CcSEcCtD
Ceftriaxone—Malaise—Temozolomide—skin cancer	0.000777	0.00224	CcSEcCtD
Ceftriaxone—Dizziness—Imiquimod—skin cancer	0.000776	0.00224	CcSEcCtD
Ceftriaxone—Infection—Dactinomycin—skin cancer	0.000772	0.00222	CcSEcCtD
Ceftriaxone—Leukopenia—Temozolomide—skin cancer	0.000771	0.00222	CcSEcCtD
Ceftriaxone—Neutropenia—Docetaxel—skin cancer	0.000769	0.00222	CcSEcCtD
Ceftriaxone—Palpitations—Temozolomide—skin cancer	0.000761	0.00219	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Dactinomycin—skin cancer	0.000761	0.00219	CcSEcCtD
Ceftriaxone—Paraesthesia—Bleomycin—skin cancer	0.000748	0.00216	CcSEcCtD
Ceftriaxone—Convulsion—Temozolomide—skin cancer	0.000746	0.00215	CcSEcCtD
Ceftriaxone—Vomiting—Imiquimod—skin cancer	0.000746	0.00215	CcSEcCtD
Ceftriaxone—Rash—Imiquimod—skin cancer	0.00074	0.00213	CcSEcCtD
Ceftriaxone—Dermatitis—Imiquimod—skin cancer	0.000739	0.00213	CcSEcCtD
Ceftriaxone—Headache—Imiquimod—skin cancer	0.000735	0.00212	CcSEcCtD
Ceftriaxone—Anaemia—Fluorouracil—skin cancer	0.000734	0.00211	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000727	0.00209	CcSEcCtD
Ceftriaxone—Discomfort—Temozolomide—skin cancer	0.000725	0.00209	CcSEcCtD
Ceftriaxone—Renal failure—Docetaxel—skin cancer	0.000721	0.00208	CcSEcCtD
Ceftriaxone—Stomatitis—Docetaxel—skin cancer	0.000714	0.00206	CcSEcCtD
Ceftriaxone—Jaundice—Docetaxel—skin cancer	0.000714	0.00206	CcSEcCtD
Ceftriaxone—Pain—Bleomycin—skin cancer	0.000713	0.00205	CcSEcCtD
Ceftriaxone—Leukopenia—Fluorouracil—skin cancer	0.00071	0.00205	CcSEcCtD
Ceftriaxone—GLUL—head—skin cancer	0.000709	0.0444	CbGeAlD
Ceftriaxone—Anaphylactic shock—Temozolomide—skin cancer	0.000703	0.00203	CcSEcCtD
Ceftriaxone—Oedema—Temozolomide—skin cancer	0.000703	0.00203	CcSEcCtD
Ceftriaxone—Infection—Temozolomide—skin cancer	0.000698	0.00201	CcSEcCtD
Ceftriaxone—Nausea—Imiquimod—skin cancer	0.000697	0.00201	CcSEcCtD
Ceftriaxone—Epistaxis—Docetaxel—skin cancer	0.000691	0.00199	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Temozolomide—skin cancer	0.000688	0.00198	CcSEcCtD
Ceftriaxone—Convulsion—Fluorouracil—skin cancer	0.000688	0.00198	CcSEcCtD
Ceftriaxone—Feeling abnormal—Bleomycin—skin cancer	0.000687	0.00198	CcSEcCtD
Ceftriaxone—Agranulocytosis—Docetaxel—skin cancer	0.000684	0.00197	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Temozolomide—skin cancer	0.00068	0.00196	CcSEcCtD
Ceftriaxone—Discomfort—Fluorouracil—skin cancer	0.000668	0.00192	CcSEcCtD
Ceftriaxone—Pain—Dactinomycin—skin cancer	0.000665	0.00192	CcSEcCtD
Ceftriaxone—Urticaria—Bleomycin—skin cancer	0.000662	0.00191	CcSEcCtD
Ceftriaxone—Haemoglobin—Docetaxel—skin cancer	0.000661	0.00191	CcSEcCtD
Ceftriaxone—Body temperature increased—Bleomycin—skin cancer	0.000659	0.0019	CcSEcCtD
Ceftriaxone—Haemorrhage—Docetaxel—skin cancer	0.000658	0.0019	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Fluorouracil—skin cancer	0.000648	0.00187	CcSEcCtD
Ceftriaxone—Oedema—Fluorouracil—skin cancer	0.000648	0.00187	CcSEcCtD
Ceftriaxone—Infection—Fluorouracil—skin cancer	0.000643	0.00185	CcSEcCtD
Ceftriaxone—Feeling abnormal—Dactinomycin—skin cancer	0.00064	0.00185	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Dactinomycin—skin cancer	0.000636	0.00183	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Fluorouracil—skin cancer	0.000634	0.00183	CcSEcCtD
Ceftriaxone—Paraesthesia—Temozolomide—skin cancer	0.000631	0.00182	CcSEcCtD
Ceftriaxone—Erythema multiforme—Docetaxel—skin cancer	0.000622	0.00179	CcSEcCtD
Ceftriaxone—Dyspepsia—Temozolomide—skin cancer	0.000619	0.00178	CcSEcCtD
Ceftriaxone—Abdominal pain—Dactinomycin—skin cancer	0.000614	0.00177	CcSEcCtD
Ceftriaxone—Body temperature increased—Dactinomycin—skin cancer	0.000614	0.00177	CcSEcCtD
Ceftriaxone—Hypersensitivity—Bleomycin—skin cancer	0.000614	0.00177	CcSEcCtD
Ceftriaxone—Flushing—Docetaxel—skin cancer	0.000611	0.00176	CcSEcCtD
Ceftriaxone—Pain—Temozolomide—skin cancer	0.000601	0.00173	CcSEcCtD
Ceftriaxone—Chills—Docetaxel—skin cancer	0.00059	0.0017	CcSEcCtD
Ceftriaxone—Pruritus—Bleomycin—skin cancer	0.00059	0.0017	CcSEcCtD
Ceftriaxone—Paraesthesia—Fluorouracil—skin cancer	0.000582	0.00168	CcSEcCtD
Ceftriaxone—Feeling abnormal—Temozolomide—skin cancer	0.000579	0.00167	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Temozolomide—skin cancer	0.000575	0.00166	CcSEcCtD
Ceftriaxone—Hypersensitivity—Dactinomycin—skin cancer	0.000573	0.00165	CcSEcCtD
Ceftriaxone—Dyspepsia—Fluorouracil—skin cancer	0.00057	0.00164	CcSEcCtD
Ceftriaxone—Dysgeusia—Docetaxel—skin cancer	0.000561	0.00162	CcSEcCtD
Ceftriaxone—Urticaria—Temozolomide—skin cancer	0.000558	0.00161	CcSEcCtD
Ceftriaxone—Body temperature increased—Temozolomide—skin cancer	0.000556	0.0016	CcSEcCtD
Ceftriaxone—Abdominal pain—Temozolomide—skin cancer	0.000556	0.0016	CcSEcCtD
Ceftriaxone—Pain—Fluorouracil—skin cancer	0.000554	0.0016	CcSEcCtD
Ceftriaxone—Feeling abnormal—Fluorouracil—skin cancer	0.000534	0.00154	CcSEcCtD
Ceftriaxone—Diarrhoea—Dactinomycin—skin cancer	0.000532	0.00153	CcSEcCtD
Ceftriaxone—Vomiting—Bleomycin—skin cancer	0.00053	0.00153	CcSEcCtD
Ceftriaxone—Anaemia—Docetaxel—skin cancer	0.000529	0.00153	CcSEcCtD
Ceftriaxone—Rash—Bleomycin—skin cancer	0.000525	0.00151	CcSEcCtD
Ceftriaxone—Dermatitis—Bleomycin—skin cancer	0.000525	0.00151	CcSEcCtD
Ceftriaxone—Hypersensitivity—Temozolomide—skin cancer	0.000518	0.00149	CcSEcCtD
Ceftriaxone—Urticaria—Fluorouracil—skin cancer	0.000515	0.00148	CcSEcCtD
Ceftriaxone—Leukopenia—Docetaxel—skin cancer	0.000513	0.00148	CcSEcCtD
Ceftriaxone—Body temperature increased—Fluorouracil—skin cancer	0.000512	0.00148	CcSEcCtD
Ceftriaxone—Palpitations—Docetaxel—skin cancer	0.000506	0.00146	CcSEcCtD
Ceftriaxone—Pruritus—Temozolomide—skin cancer	0.000497	0.00143	CcSEcCtD
Ceftriaxone—GLUL—lymph node—skin cancer	0.000496	0.0311	CbGeAlD
Ceftriaxone—Convulsion—Docetaxel—skin cancer	0.000496	0.00143	CcSEcCtD
Ceftriaxone—Nausea—Bleomycin—skin cancer	0.000495	0.00143	CcSEcCtD
Ceftriaxone—Vomiting—Dactinomycin—skin cancer	0.000494	0.00142	CcSEcCtD
Ceftriaxone—Rash—Dactinomycin—skin cancer	0.00049	0.00141	CcSEcCtD
Ceftriaxone—Diarrhoea—Temozolomide—skin cancer	0.000481	0.00139	CcSEcCtD
Ceftriaxone—Hypersensitivity—Fluorouracil—skin cancer	0.000477	0.00138	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Docetaxel—skin cancer	0.000467	0.00135	CcSEcCtD
Ceftriaxone—Oedema—Docetaxel—skin cancer	0.000467	0.00135	CcSEcCtD
Ceftriaxone—Dizziness—Temozolomide—skin cancer	0.000465	0.00134	CcSEcCtD
Ceftriaxone—Infection—Docetaxel—skin cancer	0.000464	0.00134	CcSEcCtD
Ceftriaxone—Nausea—Dactinomycin—skin cancer	0.000462	0.00133	CcSEcCtD
Ceftriaxone—Pruritus—Fluorouracil—skin cancer	0.000458	0.00132	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Docetaxel—skin cancer	0.000458	0.00132	CcSEcCtD
Ceftriaxone—Vomiting—Temozolomide—skin cancer	0.000447	0.00129	CcSEcCtD
Ceftriaxone—Rash—Temozolomide—skin cancer	0.000443	0.00128	CcSEcCtD
Ceftriaxone—Diarrhoea—Fluorouracil—skin cancer	0.000443	0.00128	CcSEcCtD
Ceftriaxone—Dermatitis—Temozolomide—skin cancer	0.000443	0.00128	CcSEcCtD
Ceftriaxone—Headache—Temozolomide—skin cancer	0.00044	0.00127	CcSEcCtD
Ceftriaxone—SLC15A2—female reproductive system—skin cancer	0.000438	0.0274	CbGeAlD
Ceftriaxone—Dizziness—Fluorouracil—skin cancer	0.000428	0.00123	CcSEcCtD
Ceftriaxone—SLC22A8—head—skin cancer	0.000421	0.0264	CbGeAlD
Ceftriaxone—Paraesthesia—Docetaxel—skin cancer	0.00042	0.00121	CcSEcCtD
Ceftriaxone—Nausea—Temozolomide—skin cancer	0.000418	0.0012	CcSEcCtD
Ceftriaxone—Vomiting—Fluorouracil—skin cancer	0.000412	0.00119	CcSEcCtD
Ceftriaxone—Dyspepsia—Docetaxel—skin cancer	0.000412	0.00119	CcSEcCtD
Ceftriaxone—Rash—Fluorouracil—skin cancer	0.000408	0.00118	CcSEcCtD
Ceftriaxone—Dermatitis—Fluorouracil—skin cancer	0.000408	0.00118	CcSEcCtD
Ceftriaxone—Headache—Fluorouracil—skin cancer	0.000406	0.00117	CcSEcCtD
Ceftriaxone—Pain—Docetaxel—skin cancer	0.0004	0.00115	CcSEcCtD
Ceftriaxone—Feeling abnormal—Docetaxel—skin cancer	0.000385	0.00111	CcSEcCtD
Ceftriaxone—Nausea—Fluorouracil—skin cancer	0.000385	0.00111	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Docetaxel—skin cancer	0.000382	0.0011	CcSEcCtD
Ceftriaxone—Abdominal pain—Docetaxel—skin cancer	0.00037	0.00106	CcSEcCtD
Ceftriaxone—Body temperature increased—Docetaxel—skin cancer	0.00037	0.00106	CcSEcCtD
Ceftriaxone—SLC15A2—head—skin cancer	0.000366	0.0229	CbGeAlD
Ceftriaxone—Hypersensitivity—Docetaxel—skin cancer	0.000344	0.000992	CcSEcCtD
Ceftriaxone—Pruritus—Docetaxel—skin cancer	0.000331	0.000953	CcSEcCtD
Ceftriaxone—Diarrhoea—Docetaxel—skin cancer	0.00032	0.000922	CcSEcCtD
Ceftriaxone—Dizziness—Docetaxel—skin cancer	0.000309	0.000891	CcSEcCtD
Ceftriaxone—ALB—lymph node—skin cancer	0.000307	0.0192	CbGeAlD
Ceftriaxone—Vomiting—Docetaxel—skin cancer	0.000297	0.000856	CcSEcCtD
Ceftriaxone—Rash—Docetaxel—skin cancer	0.000295	0.000849	CcSEcCtD
Ceftriaxone—Dermatitis—Docetaxel—skin cancer	0.000294	0.000849	CcSEcCtD
Ceftriaxone—Headache—Docetaxel—skin cancer	0.000293	0.000844	CcSEcCtD
Ceftriaxone—Nausea—Docetaxel—skin cancer	0.000278	0.0008	CcSEcCtD
Ceftriaxone—SLC15A2—lymph node—skin cancer	0.000256	0.0161	CbGeAlD
